Literature DB >> 24145382

1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages.

Julie Lalande1, Hélène Halley2, Stéphane Balayssac1, Véronique Gilard1, Sébastien Déjean3, Robert Martino1, Bernard Francés2, Jean-Michel Lassalle2, Myriam Malet-Martino1.   

Abstract

In the quest for biomarkers of onset and progression of Alzheimer's disease, a 1H NMR-based metabolomic study was performed on the simple single-transgenic Tg2576 mouse model. These mice develop a slow cognitive decline starting by 6 months and express amyloid plaques from 10 months of age. The metabolic profiles of extracts from five brain regions (frontal cortex, rhinal cortex, hippocampus, midbrain, and cerebellum) of Tg2576 male mice were compared to those of controls, at 1, 3, 6 and 11 months of age. The most obvious differences were due to brain regions. Age was also a discriminating parameter. Metabolic perturbations were already detected in the hippocampus and the rhinal cortex of transgenic mice as early as 1 month of age with decreased concentrations of glutamate (Glu) and N-acetylaspartate (NAA) compared to those in wild-type animals. Metabolic changes were more numerous in the hippocampus and the rhinal cortex of 3 month-old transgenic mice and involved Glu, NAA, myo-inositol, creatine, phosphocholine, and γ-aminobutyric acid (only in the hippocampus) whose concentrations decreased. A metabolic disruption characterized by an increase in the hippocampal concentrations of Glu, creatine, and taurine was detected in 6 month-old transgenic mice. At this time point, the chemical profile of the cerebellum was slightly affected. At 11 months, all the brain regions analyzed (except the frontal cortex) were metabolically altered, with mainly a marked increase in the formation of the neuroprotective metabolites creatine and taurine. Our findings demonstrate that metabolic modifications occur long before the onset of behavioral impairment.

Entities:  

Keywords:  $^1$H NMR; Alzheimer's disease; AβPPswe Tg2576 mouse model; biomarkers; metabolomics

Mesh:

Substances:

Year:  2014        PMID: 24145382     DOI: 10.3233/JAD-130023

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

1.  NMR-based metabolomics reveals brain region-specific metabolic alterations in streptozotocin-induced diabetic rats with cognitive dysfunction.

Authors:  Hong Zheng; Qiuting Lin; Dan Wang; Pengtao Xu; Liangcai Zhao; Wenyi Hu; Guanghui Bai; Zhihan Yan; Hongchang Gao
Journal:  Metab Brain Dis       Date:  2017-01-09       Impact factor: 3.584

2.  ¹H- and ¹³C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimer's disease.

Authors:  A Doert; U Pilatus; F Zanella; W E Müller; G P Eckert
Journal:  J Neural Transm (Vienna)       Date:  2015-03-06       Impact factor: 3.575

3.  Alterations in mitochondrial number and function in Alzheimer's disease fibroblasts.

Authors:  Nora E Gray; Joseph F Quinn
Journal:  Metab Brain Dis       Date:  2015-04-12       Impact factor: 3.584

4.  Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.

Authors:  Kai Lun Chang; Ling Rong Wong; Hai Ning Pee; Shili Yang; Paul Chi-Lui Ho
Journal:  Mol Neurobiol       Date:  2019-04-23       Impact factor: 5.590

5.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

6.  Identification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis.

Authors:  Thomas Cruz; Marie Gleizes; Stéphane Balayssac; Etienne Mornet; Grégory Marsal; José Luis Millán; Myriam Malet-Martino; Lionel G Nowak; Véronique Gilard; Caroline Fonta
Journal:  J Neurochem       Date:  2017-03       Impact factor: 5.372

Review 7.  Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.

Authors:  Marc-Emmanuel Dumas; Laetitia Davidovic
Journal:  J Neuroimmune Pharmacol       Date:  2015-01-24       Impact factor: 4.147

8.  The Impact of the hAPP695SW Transgene and Associated Amyloid-β Accumulation on Murine Hippocampal Biochemical Pathways.

Authors:  Mona Khorani; Gerd Bobe; Donald G Matthews; Armando Alcazar Magana; Maya Caruso; Nora E Gray; Joseph F Quinn; Jan F Stevens; Amala Soumyanath; Claudia S Maier
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

9.  Oxidative Stress during the Progression of β-Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease.

Authors:  Sara Porcellotti; Francesca Fanelli; Anna Fracassi; Sara Sepe; Francesco Cecconi; Cinzia Bernardi; AnnaMaria Cimini; Maria Paola Cerù; Sandra Moreno
Journal:  Oxid Med Cell Longev       Date:  2015-04-20       Impact factor: 6.543

10.  Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease.

Authors:  Stewart F Graham; Olivier P Chevallier; Christopher T Elliott; Christian Hölscher; Janet Johnston; Bernadette McGuinness; Patrick G Kehoe; Anthony Peter Passmore; Brian D Green
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.